Core Viewpoint - The company, Jianfa Zhixin, is officially launching its IPO process on the Shenzhen Stock Exchange's ChiNext board, focusing on the medical device distribution industry and aiming to enhance its digital capabilities and service offerings in the healthcare sector [1][2]. Group 1: Company Overview - Jianfa Zhixin was established in 2010 and primarily engages in direct sales and distribution of medical devices, providing services such as SPD to hospitals [2]. - The company has developed a nationwide distribution network, serving over 3,300 medical institutions across 31 provinces in China, with a focus on high-value interventional products [2]. - Jianfa Zhixin has established long-term partnerships with over 100 well-known domestic and international medical device manufacturers, leveraging its strong channel coverage and professional operations [2]. Group 2: Financial Performance - From 2022 to 2024, Jianfa Zhixin's projected revenue is expected to grow from 11.882 billion yuan to 17.923 billion yuan, reflecting a compound annual growth rate (CAGR) of 22.81% [3]. - The company's main revenue source is its direct sales business, which is projected to increase from 7.797 billion yuan in 2022 to 11.032 billion yuan in 2024 [3]. - The revenue growth is attributed to the rapid increase in authorized brands and product lines, as well as the integrated development of direct and distribution businesses [3]. Group 3: Investment and Technology - Jianfa Zhixin plans to use the funds raised from the IPO to invest in digitalization and centralized management of medical consumables, enhancing its management capabilities [1][5]. - The company has developed various proprietary software systems to improve its information management and operational efficiency, holding 45 software copyrights as of the date of the prospectus [5]. - The planned allocation of raised funds includes 140 million yuan for information system upgrades, 104 million yuan for centralized operation services, and 240 million yuan for working capital [5]. Group 4: Future Outlook - Jianfa Zhixin aims to become a leading medical device distribution service provider in China by enhancing its service attributes and expanding its product diversification and integration along the supply chain [1][3]. - The company is focused on scaling its operations while ensuring compliance and information-driven management in the evolving healthcare landscape [3].

Core Viewpoint - The company plans to publicly issue up to 63,193,277 shares of common stock to raise funds for its main business projects and working capital, with a total investment of 48,423.71 million yuan allocated for various projects [1] Group 1: Investment Projects - The company intends to invest 14,015.95 million yuan in an information system upgrade project, which will take three years to complete and aims to enhance the core business platform and data platform using advanced technologies like big data and IoT [1][4] - The medical consumables centralized operation service project will receive an investment of 10,407.76 million yuan over two years, focusing on building an information platform and smart hardware for hospitals to manage medical consumables efficiently [5][6] Group 2: Policy and Industry Support - The national policy supports the advancement of medical information technology, which provides a solid foundation for the company's information system upgrade project [2] - The company has a well-established information technology foundation and extensive experience in information system construction, which will support the successful implementation of the upgrade project [3] Group 3: Talent and Technical Capability - The company has a complete talent pool for information technology, ensuring that the team can provide technical support during the construction and operation of the information system [3] - The project aims to improve various management levels, including operational, financial, and decision-making management, thereby supporting the company's rapid business expansion [3] Group 4: Financial Projections - The centralized operation service project is expected to generate an average annual sales revenue of 57.85 million yuan, with a financial internal rate of return of 25.34% after tax [9]